Metformin: Candidate host-directed therapy for tuberculosis in&#160;diabetes and non-diabetes patients (Q38976395)

8 September 2017

1 reference

title

Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients (English)

1 reference

8 September 2017

0 references

1 reference

Blanca I Restrepo

1

1 reference

PubMed ID

27720378

8 September 2017

language of work or name

1 reference

28 September 2016

1 reference

8 September 2017

1 reference

8 September 2017

101S

1 reference

8 September 2017

S69-S72

1 reference

Advancing host-directed therapy for tuberculosis

8 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Inflammation and tuberculosis: host-directed therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Increased levels of circulating interleukin-18 in patients with advanced tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

IL-17 and Th17 cells in tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Increased levels of BAFF and APRIL related to human active pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Oxidative stress and diabetic complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Evidence for oxidative stress and defective antioxidant response in guinea pigs with tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Metformin as adjunct antituberculosis therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Role of AMP-activated protein kinase in mechanism of metformin action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Normalization of CD4+ T cell metabolism reverses lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Metformin increases phagocytosis and acidifies lysosomal/endosomal compartments in AMPK-dependent manner in rat primary microglia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Antigen-specific CD8(+) T cells and protective immunity to tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Lactic acidosis induced by metformin: incidence, management and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

AMP-activated protein kinase and muscle glucose uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Metformin and cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Impact of diabetes on the natural history of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Reduced Mycobacterium tuberculosis association with monocytes from diabetes patients that have poor glucose control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Phagocytosis via complement or Fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Diabetic control and risk of tuberculosis: a cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

The impact of diabetes on tuberculosis treatment outcomes: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Rapamycin-induced enhancement of vaccine efficacy in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Standards of medical care in diabetes--2014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.09.008

10.1016/J.TUBE.2016.09.008

7 January 2021

Identifiers

DOI

1 reference

release_hfkk7kkblbfmzivm7fprv2tmjy

8 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hfkk7kkblbfmzivm7fprv2tmjy

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

27720378

1 reference

PubMed ID

27720378